Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.57 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30779573 | 1.00 | LRRK2 (0.57) | LRRK2SGMS2RXFP1GAASCD | |
| SCHEMBL21644687 | 0.92 | SGMS2 (0.62) | LRRK2SGMS2GAAMEN1KMT2A | |
| SCHEMBL30779582 | 0.92 | SGMS2 (0.62) | LRRK2SGMS2GAAMEN1KMT2A | |
| SCHEMBL21644662 | 0.89 | LRRK2 (0.70) | LRRK2SGMS2 | |
| SCHEMBL30779633 | 0.89 | LRRK2 (0.70) | LRRK2SGMS2 | |
| SCHEMBL21644602 | 0.87 | SGMS2 (0.56) | LRRK2SGMS2RXFP1GAAMEN1 | |
| SCHEMBL30779528 | 0.87 | SGMS2 (0.56) | LRRK2SGMS2RXFP1GAAMEN1 | |
| SCHEMBL28412383 | 0.85 | LRRK2 (0.59) | LRRK2SGMS2RXFP1GAAMEN1 | |
| SCHEMBL21644641 | 0.84 | LRRK2 (0.47) | LRRK2SGMS2 | |
| SCHEMBL30779643 | 0.84 | LRRK2 (0.47) | LRRK2SGMS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | LRRK2 183/4885SGMS2 3734/4885RXFP1 4722/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | LRRK2 183/4885SGMS2 3734/4885RXFP1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.